Form 4: Amneal Pharmaceuticals Director Gautam Patel Sells Shares Under 10b5-1 Plan

Director Gautam Patel of Amneal Pharmaceuticals sold a total of 8,668 shares of Class A Common Stock on May 2nd and 5th, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• Gautam Patel, a director of Amneal Pharmaceuticals, sold 3,768 shares of Class A Common Stock on May 2, 2025, at a weighted average price of $8 per share.
• He then sold an additional 4,900 shares of Class A Common Stock on May 5, 2025, also at a weighted average price of $8 per share.
• These transactions were executed automatically under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on August 15, 2024.
• Following these sales, Patel directly owns 1,720,218 shares of Amneal Pharmaceuticals Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were part of a pre-planned trading arrangement. It doesn't necessarily reflect a positive or negative outlook on the company's future.

Industry Context

Sales by company insiders are routinely monitored by investors. Sales under 10b5-1 plans are less likely to be interpreted as a negative signal, as these plans are pre-arranged and often used for diversification or liquidity purposes.

Stakeholder Impact

• The sale of shares by a director could have a minor impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates potential concerns.

Key Dates

Keywords

Amneal Pharmaceuticals, AMRX, Gautam Patel, Form 4, Share Sale, Director, 10b5-1 Plan, Class A Common Stock